Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rocio D Marchese

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
The Journal of Infectious Diseases|January 22, 2010
Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = yearsSusan B Manoff, Charles Liss, Michael J Caulfield, et al.
Human Vaccines & Immunotherapeutics|March 23, 2016
Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomesKaren L Ciprero, Rocio D Marchese, Patrick Richard, et al.
The Pediatric Infectious Disease Journal|March 6, 2015
Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccineAjoke Sobanjo-ter Meulen, Timo Vesikari, Edgardo A Malacaman, et al.
Vaccine|April 28, 2015
Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adultsRichard McFetridge, Ajoke Sobanjo-Ter Meulen, Steven D Folkerth, et al.
Vaccine|September 25, 2018
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infantsDavid Greenberg, Patricia A Hoover, Timo Vesikari, et al.
The Journal of Infectious Diseases|August 29, 2009
Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccineAdriana Weinberg, Jane H Zhang, Michael N Oxman, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
The Journal of Infectious Diseases|January 22, 2010
Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = yearsSusan B Manoff, Charles Liss, Michael J Caulfield, et al.
Human Vaccines & Immunotherapeutics|March 23, 2016
Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomesKaren L Ciprero, Rocio D Marchese, Patrick Richard, et al.
The Pediatric Infectious Disease Journal|March 6, 2015
Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccineAjoke Sobanjo-ter Meulen, Timo Vesikari, Edgardo A Malacaman, et al.
Vaccine|April 28, 2015
Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adultsRichard McFetridge, Ajoke Sobanjo-Ter Meulen, Steven D Folkerth, et al.
Vaccine|September 25, 2018
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infantsDavid Greenberg, Patricia A Hoover, Timo Vesikari, et al.
The Journal of Infectious Diseases|August 29, 2009
Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccineAdriana Weinberg, Jane H Zhang, Michael N Oxman, et al.
Pageof 2